title: [Neuroleptic properties of Y-20024, a new benzofurancarboxamide derivative].
abstract: N-[(1-butyl-2-pyrrolidinyl)methyl]-2-methyl-5-sulfamoyl-2,3- dihydrobenzofuran-7-carboxamide hydrochloride (Y-20024) was synthesized in our laboratories in anticipation of developing a new psychotropic drug. In the present study, the pharmacological properties of Y-20024 were compared with those of sulpiride (SPR) and haloperidol (HPD). Administered orally, Y-20024 was 10 times stronger than SPR in inhibiting apomorphine (0.5 mg/kg, s.c.)-induced hyperactivity in mice; administered intravenously or intracerebroventricularly, it was 2 times or one third as strong, respectively. Y-20024 was almost equipotent to SPR in antagonizing apomorphine (0.1 mg/kg, s.c.)-induced vomiting in dogs. Combined with methamphetamine (5 mg/kg, i.p.), Y-20024 and SPR induced mortality dose-dependently in rats, but HPD did not. The mammotropic activity of Y-20024 administered orally once a day for 5 days was almost equipotent to that of SPR. From these results, Y-20024, pharmacologically similar to SPR, but superior in bioavailability and penetration through the blood brain barrier, may have potential usefulness as an antipsychotic drug.
authors.affiliation: Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd., Fukuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Fukuda
authors.forename: Y
authors.initials: Y
authors.lastname: Morimoto
authors.forename: T
authors.initials: T
authors.lastname: Morimoto
authors.forename: H
authors.initials: H
authors.lastname: Shoji
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Tahara
authors.forename: M
authors.initials: M
authors.lastname: Setoguchi
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001572:Benzofurans / Q000008:administration & dosage / Q000494:pharmacology*; D001831:Body Temperature / Q000187:drug effects; D002375:Catalepsy / Q000188:drug therapy; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D008297:Male; D008694:Methamphetamine / Q000037:antagonists & inhibitors / Q000633:toxicity; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D011388:Prolactin / Q000378:metabolism; D011759:Pyrrolidines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012653:Self Stimulation / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D001572:Benzofurans; D011759:Pyrrolidines; C062632:Y 20024; D008694:Methamphetamine; D011388:Prolactin; D001058:Apomorphine